Avadel Pharmaceuticals (AVDL): Bathi resik saben saham sajrone 12 wulan pungkasan

Simbol lan logo merek Avadel Pharmaceuticals (AVDL)

Net income per share over 12 months demonstrates the asset's dynamics, where the -0.01 level captures recent values for Avadel Pharmaceuticals (AVDL). A neutral geopolitical backdrop and the humanitarian status of the therapy support exchange rate stability. Market share growth is driven by the convenience of administering the Lumryz drug. High margins with a small workforce are achieved through a patented extended-release formula.

AVDL (Avadel Corp) riwayat Bathi resik saben saham sajrone 12 wulan pungkasan saka 04.07.2022 nganti 28.02.2026

Rincian analitis lan laporan data perusahaan Avadel Pharma (AVDL)

- kuotasi saiki lan rata-rata prakiraan nilai:
Analisis kabeh metrik perusahaan:Avadel Pharmaceuticals plc - AVDL
Produk seri Avadel Pharmaceuticals PLC

The selection of high-quality issuers is based on an analysis of specific yield, where the trailing 12-month EPS reflects the net profit allocated per share per year. For Avadel Pharmaceuticals (AVDL), this metric verifies the efficiency of cost management regarding ESG optimization of supply chains and bioethical drug development, allowing investors to assess the real profitability of the business through the dynamics of this chart.